What are the major opportunities in the Ischemic Heart Disease (IHD) Drugs market? What are the strategies for the Ischemic Heart Disease (IHD) Drugs market?

For detailed insights on the major opportunities and strategies in the Ischemic Heart Disease (IHD) Drugs market, Read More

How does the Ischemic Heart Disease (IHD) Drugs market relate to the overall economy and other similar markets?

For detailed insights on Ischemic Heart Disease (IHD) Drugs's relation to the overall economy and other similar markets, Read More

What are the key dynamics influencing the Ischemic Heart Disease (IHD) Drugs market growth? SWOT analysis of the Ischemic Heart Disease (IHD) Drugs market.

For detailed insights on the key dynamics influencing the Ischemic Heart Disease (IHD) Drugs market growth and SWOT analysis of the Ischemic Heart Disease (IHD) Drugs industry, Read More

Ischemic Heart Disease (IHD) Drugs Market Global Report 2026 Market Report Infographic Image

Item added to cart!

Published : February 2026

Pages : 175

Format : PDF

Delivery Time : 2-3 Business Days

Report Price : $4490.00

Purchase This Report Download Sample PDF

Purchase This Report

Ischemic Heart Disease (IHD) Drugs Market Report 2026

Name: Ischemic Heart Disease (IHD) Drugs Market Report 2026
Brand: The Business Research Company
Price: 4490.00 USD
Availability: InStock

Global Outlook – By Drug Class (Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, Angiotensin-converting enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Vasodilators, Antithrombotic Agents), By Disease Class (Angina Pectoris, Myocardial Infarction), By End User (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy) - Market Size, Trends, And Global Forecast 2025-2034

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

Ischemic Heart Disease (IHD) Drugs Market Overview

• Ischemic Heart Disease (IHD) Drugs market size has reached to $6.65 billion in 2025

• Expected to grow to $7.99 billion in 2030 at a compound annual growth rate (CAGR) of 3.7%

• Growth Driver: Rising Heart Failure Cases Drive Surge In Ischemic Heart Disease (IHD) Drugs Market Growth

• Market Trend: Regulatory Momentum And Indication Expansions Strengthening Therapeutic Advancements In Ischemic Heart Disease

• North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Ischemic Heart Disease (IHD) Drugs Market?

Ischemic heart disease (IHD) drugs are medications used to manage and treat a condition characterized by reduced blood flow to the heart muscle, often due to coronary artery narrowing. These drugs aim to alleviate symptoms, reduce the risk of complications such as heart attacks, and improve overall cardiac function.

The main types of drug classes included in ischemic heart disease (IHD) drugs are anti-dyslipidemic drugs, calcium channel blockers, beta-blockers, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), vasodilators, and antithrombotic agents. Anti-dyslipidemic drugs are pharmacological agents that target and lower abnormal levels of lipids (such as cholesterol and triglycerides) in the bloodstream to reduce the risk of cardiovascular disease. These are used to treat various classes of disease, including angina pectoris and myocardial infarction, and are used by several end users, such as hospital pharmacies, retail pharmacies, and online pharmacies.

Ischemic Heart Disease (IHD) Drugs Market Global Report 2026 Market Report bar graph

What Is The Ischemic Heart Disease (IHD) Drugs Market Size and Share 2026?

The ischemic heart disease (ihd) drugs market size has grown steadily in recent years. It will grow from $6.65 billion in 2025 to $6.9 billion in 2026 at a compound annual growth rate (CAGR) of 3.7%. The growth in the historic period can be attributed to rising prevalence of coronary artery disease, increasing geriatric population, growing awareness of cardiovascular health, high incidence of lifestyle-related risk factors, availability of generic drugs.

What Is The Ischemic Heart Disease (IHD) Drugs Market Growth Forecast?

The ischemic heart disease (ihd) drugs market size is expected to see steady growth in the next few years. It will grow to $7.99 billion in 2030 at a compound annual growth rate (CAGR) of 3.7%. The growth in the forecast period can be attributed to advancements in precision medicine, integration of digital health solutions, growth in combination therapy adoption, development of novel drug delivery systems, expansion of telehealth and remote monitoring. Major trends in the forecast period include personalized cardiac therapy, combination drug formulations, telemedicine-enabled cardiac care, cardiovascular risk prediction & monitoring, minimally invasive drug delivery.

Book your 30 minutes free consultation with our research experts

Global Ischemic Heart Disease (IHD) Drugs Market Segmentation

1) By Drug Class: Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, Angiotensin-converting enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Vasodilators, Antithrombotic Agents

2) By Disease Class: Angina Pectoris, Myocardial Infarction

3) By End User: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

Subsegments:

1) By Anti-Dyslipidemic Drugs: Statins, Fibrates, Niacin, Cholesterol Absorption Inhibitors

2) By Calcium Channel Blockers: Dihydropyridines, Non-Dihydropyridines

3) By Beta-Blockers: Cardioselective Beta-Blockers, Non-Selective Beta-Blockers, Vasodilating Beta-Blockers

4) By Angiotensin-Converting Enzyme (ACE) Inhibitors: Enalapril, Lisinopril, Ramipril

5) By Angiotensin II Receptor Blockers (ARBs): Losartan, Valsartan, Irbesartan

6) By Vasodilators: Nitroglycerin, Isosorbide Dinitrate, Hydralazine

7) By Antithrombotic Agents: Antiplatelet Drugs, Anticoagulants

What Is The Driver Of The Ischemic Heart Disease (IHD) Drugs Market?

The increasing incidence of heart failure is expected to propel the growth of the ischemic heart disease (IHD) drug market going forward. Heart failure is a chronic condition in which the heart muscle is unable to pump enough blood to meet the body's needs for blood and oxygen. This can lead to fatigue, shortness of breath, and difficulty performing everyday activities. Ischemic heart disease (IHD) drugs play an important role in the treatment of heart failure. To reduce the risk factors and symptoms of ischemic heart disease, these medications can help avoid heart failure. Ischemic Heart Disease (IHD) drugs inhibit the pacemaker activity of the heart and are beneficial in heart failure patients with reduced ejection fractions and high resting heart rates after a tolerated beta-blocker. For instance, in September 2023, according to the Heart Failure Society of America, a US-based organization, 6.7 million Americans over 20 years of age have heart failure (HF), and the prevalence is expected to rise to 8.5 million Americans by 2030. Therefore, the increasing incidence of heart failure is driving the growth of the ischemic heart disease (IHD) drug industry.

Key Players In The Global Ischemic Heart Disease (IHD) Drugs Market

Major companies operating in the ischemic heart disease (ihd) drugs market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sandoz Inc., Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Ltd., Cipla Limited, Lupin Limited, Recordati S.p.A., Zydus Lifesciences Limited, Glenmark Pharmaceuticals Ltd., Aurobindo Pharma Limited, Alembic Pharmaceuticals Ltd., Accord Healthcare Limited, Macleods Pharmaceuticals Ltd., Novitium Pharma LLC

Global Ischemic Heart Disease (IHD) Drugs Market Trends and Insights

Major companies operating in the ischemic heart disease (IHD) drugs market are focusing on advancing regulatory approvals and expanding drug indications to strengthen therapeutic options and capture greater market share. For instance, in June 2023, Bristol Myers Squibb, a US-based biopharmaceutical company, announced that the European Commission approved Camzyos (mavacamten), the first allosteric, selective cardiac myosin inhibitor for treating symptomatic NYHA class II–III obstructive hypertrophic cardiomyopathy (HCM). In the same year in the U.S., the FDA approved a supplemental new drug application based on Phase 3 VALOR HCM data showing a significant reduction in eligibility for septal reduction therapy among treated patients. Therefore, increasing regulatory momentum and label expansions for myosin inhibitors are driving growth in the IHD drug market.

Need data on a specific region in this market?

Request Regional Data

What Are Latest Mergers And Acquisitions In The Ischemic Heart Disease (IHD) Drugs Market?

In March 2024, Novo Nordisk, a Denmark-based pharmaceutical company, acquired cardior pharmaceuticals for an undisclosed amount. The acquisition is a significant step in Novo Nordisk's strategy to establish and expand its portfolio in cardiovascular disease, which is a leading cause of mortality worldwide. Cardior pharmaceuticals is a Germany-based pharmaceutical company manufacturing cardiovascular drugs for IHD.

Regional Insights

North America was the largest region in the ischemic heart disease (IHD) drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Ischemic Heart Disease (IHD) Drugs Market?

The ischemic heart disease (IHD) drugs market consists of sales of antiarrhythmic drugs, anticoagulants, anti-anginal medications, nitroglycerin and nitrates, statins, and antiplatelet agents. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Ischemic Heart Disease (IHD) Drugs Market Report 2026?

The ischemic heart disease (ihd) drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the ischemic heart disease (ihd) drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.

Author : Abhilash Pyata

Ischemic Heart Disease (IHD) Drugs Market Report Forecast Analysis

Report Attribute	Details
Market Size Value In 2026	$6.9 billion
Revenue Forecast In 2035	$7.99 billion
Growth Rate	CAGR of 3.7% from 2026 to 2035
Base Year For Estimation	2025
Actual Estimates/Historical Data	2020-2025
Forecast Period	2026 - 2030 - 2035
Market Representation	Revenue in USD Billion and CAGR from 2026 to 2035
Segments Covered	Drug Class, Disease Class, End User
Regional Scope	Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Country Scope	The countries covered in the report are Australia, Brazil, China, France, Germany, India, ...
Key Companies Profiled	Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmace
Customization Scope	Request for Customization
Pricing And Purchase Options	Explore Purchase Options

1. Executive Summary

1.1. Key Market Insights (2020-2035)

1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots

1.3. Major Factors Driving the Market

1.4. Top Three Trends Shaping the Market

2. Ischemic Heart Disease (IHD) Drugs Market Characteristics

2.1. Market Definition & Scope

2.2. Market Segmentations

2.3. Overview of Key Products and Services

2.4. Global Ischemic Heart Disease (IHD) Drugs Market Attractiveness Scoring And Analysis

2.4.1. Overview of Market Attractiveness Framework

2.4.2. Quantitative Scoring Methodology

2.4.3. Factor-Wise Evaluation

Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation

2.4.4. Market Attractiveness Scoring and Interpretation

2.4.5. Strategic Implications and Recommendations

3. Ischemic Heart Disease (IHD) Drugs Market Supply Chain Analysis

3.1. Overview of the Supply Chain and Ecosystem

3.2. List Of Key Raw Materials, Resources & Suppliers

3.3. List Of Major Distributors and Channel Partners

3.4. List Of Major End Users

4. Global Ischemic Heart Disease (IHD) Drugs Market Trends And Strategies

4.1. Key Technologies & Future Trends

4.1.1 Artificial Intelligence & Autonomous Intelligence

4.1.2 Biotechnology, Genomics & Precision Medicine

4.1.3 Digitalization, Cloud, Big Data & Cybersecurity

4.1.4 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems

4.1.5 Industry 4.0 & Intelligent Manufacturing

4.2. Major Trends

4.2.1 Personalized Cardiac Therapy

4.2.2 Combination Drug Formulations

4.2.3 Telemedicine-Enabled Cardiac Care

4.2.4 Cardiovascular Risk Prediction & Monitoring

4.2.5 Minimally Invasive Drug Delivery

5. Ischemic Heart Disease (IHD) Drugs Market Analysis Of End Use Industries

5.1 Hospital Pharmacy

5.2 Retail Pharmacy

5.3 Online Pharmacy

5.4 Cardiology Clinics

5.5 Ambulatory Care Centers

6. Ischemic Heart Disease (IHD) Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Ischemic Heart Disease (IHD) Drugs Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

7.1. Global Ischemic Heart Disease (IHD) Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)

7.2. Global Ischemic Heart Disease (IHD) Drugs Market Size, Comparisons And Growth Rate Analysis

7.3. Global Ischemic Heart Disease (IHD) Drugs Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)

7.4. Global Ischemic Heart Disease (IHD) Drugs Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Ischemic Heart Disease (IHD) Drugs Total Addressable Market (TAM) Analysis for the Market

8.1. Definition and Scope of Total Addressable Market (TAM)

8.2. Methodology and Assumptions

8.3. Global Total Addressable Market (TAM) Estimation

8.4. TAM vs. Current Market Size Analysis

8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Ischemic Heart Disease (IHD) Drugs Market Segmentation

9.1. Global Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Anti-Dyslipidemic Drugs, Calcium Channel Blockers, Beta-Blockers, Angiotensin-converting enzyme (ACE) Inhibitors, Angiotensin II Receptor Blockers (ARBs), Vasodilators, Antithrombotic Agents

9.2. Global Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Angina Pectoris, Myocardial Infarction

9.3. Global Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Hospital Pharmacy, Retail Pharmacy, Online Pharmacy

9.4. Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Anti-Dyslipidemic Drugs, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Statins, Fibrates, Niacin, Cholesterol Absorption Inhibitors

9.5. Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Calcium Channel Blockers, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Dihydropyridines, Non-Dihydropyridines

9.6. Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Beta-Blockers, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Cardioselective Beta-Blockers, Non-Selective Beta-Blockers, Vasodilating Beta-Blockers

9.7. Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Angiotensin-Converting Enzyme (ACE) Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Enalapril, Lisinopril, Ramipril

9.8. Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Angiotensin II Receptor Blockers (ARBs), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Losartan, Valsartan, Irbesartan

9.9. Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Vasodilators, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Nitroglycerin, Isosorbide Dinitrate, Hydralazine

9.10. Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Antithrombotic Agents, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Antiplatelet Drugs, Anticoagulants

10. Ischemic Heart Disease (IHD) Drugs Market Regional And Country Analysis

10.1. Global Ischemic Heart Disease (IHD) Drugs Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

10.2. Global Ischemic Heart Disease (IHD) Drugs Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Ischemic Heart Disease (IHD) Drugs Market

11.1. Asia-Pacific Ischemic Heart Disease (IHD) Drugs Market Overview

Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

11.2. Asia-Pacific Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Segmentation By Disease Class, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Ischemic Heart Disease (IHD) Drugs Market

12.1. China Ischemic Heart Disease (IHD) Drugs Market Overview

Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

12.2. China Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Segmentation By Disease Class, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Ischemic Heart Disease (IHD) Drugs Market

13.1. India Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Segmentation By Disease Class, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Ischemic Heart Disease (IHD) Drugs Market

14.1. Japan Ischemic Heart Disease (IHD) Drugs Market Overview

14.2. Japan Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Segmentation By Disease Class, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Ischemic Heart Disease (IHD) Drugs Market

15.1. Australia Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Segmentation By Disease Class, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Ischemic Heart Disease (IHD) Drugs Market

16.1. Indonesia Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Segmentation By Disease Class, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Ischemic Heart Disease (IHD) Drugs Market

17.1. South Korea Ischemic Heart Disease (IHD) Drugs Market Overview

17.2. South Korea Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Segmentation By Disease Class, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Ischemic Heart Disease (IHD) Drugs Market

18.1. Taiwan Ischemic Heart Disease (IHD) Drugs Market Overview

18.2. Taiwan Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Segmentation By Disease Class, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Ischemic Heart Disease (IHD) Drugs Market

19.1. South East Asia Ischemic Heart Disease (IHD) Drugs Market Overview

19.2. South East Asia Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Segmentation By Disease Class, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Ischemic Heart Disease (IHD) Drugs Market

20.1. Western Europe Ischemic Heart Disease (IHD) Drugs Market Overview

20.2. Western Europe Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Segmentation By Disease Class, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Ischemic Heart Disease (IHD) Drugs Market

21.1. UK Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Segmentation By Disease Class, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Ischemic Heart Disease (IHD) Drugs Market

22.1. Germany Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Segmentation By Disease Class, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Ischemic Heart Disease (IHD) Drugs Market

23.1. France Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Segmentation By Disease Class, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Ischemic Heart Disease (IHD) Drugs Market

24.1. Italy Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Segmentation By Disease Class, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Ischemic Heart Disease (IHD) Drugs Market

25.1. Spain Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Segmentation By Disease Class, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Ischemic Heart Disease (IHD) Drugs Market

26.1. Eastern Europe Ischemic Heart Disease (IHD) Drugs Market Overview

26.2. Eastern Europe Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Segmentation By Disease Class, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Ischemic Heart Disease (IHD) Drugs Market

27.1. Russia Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Segmentation By Disease Class, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Ischemic Heart Disease (IHD) Drugs Market

28.1. North America Ischemic Heart Disease (IHD) Drugs Market Overview

28.2. North America Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Segmentation By Disease Class, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Ischemic Heart Disease (IHD) Drugs Market

29.1. USA Ischemic Heart Disease (IHD) Drugs Market Overview

29.2. USA Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Segmentation By Disease Class, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Ischemic Heart Disease (IHD) Drugs Market

30.1. Canada Ischemic Heart Disease (IHD) Drugs Market Overview

30.2. Canada Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Segmentation By Disease Class, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Ischemic Heart Disease (IHD) Drugs Market

31.1. South America Ischemic Heart Disease (IHD) Drugs Market Overview

31.2. South America Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Segmentation By Disease Class, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Ischemic Heart Disease (IHD) Drugs Market

32.1. Brazil Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Segmentation By Disease Class, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Ischemic Heart Disease (IHD) Drugs Market

33.1. Middle East Ischemic Heart Disease (IHD) Drugs Market Overview

33.2. Middle East Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Segmentation By Disease Class, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Ischemic Heart Disease (IHD) Drugs Market

34.1. Africa Ischemic Heart Disease (IHD) Drugs Market Overview

34.2. Africa Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Segmentation By Disease Class, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Ischemic Heart Disease (IHD) Drugs Market Regulatory and Investment Landscape

36. Ischemic Heart Disease (IHD) Drugs Market Competitive Landscape And Company Profiles

36.1. Ischemic Heart Disease (IHD) Drugs Market Competitive Landscape And Market Share 2024

36.1.1. Top 10 Companies (Ranked by revenue/share)

36.2. Ischemic Heart Disease (IHD) Drugs Market - Company Scoring Matrix

36.2.1. Market Revenues

36.2.2. Product Innovation Score

36.2.3. Brand Recognition

36.3. Ischemic Heart Disease (IHD) Drugs Market Company Profiles

36.3.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis

36.3.2. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis

36.3.3. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis

36.3.4. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis

36.3.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

37. Ischemic Heart Disease (IHD) Drugs Market Other Major And Innovative Companies

Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Eli Lilly and Company, Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sandoz Inc., Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Ltd., Cipla Limited, Lupin Limited, Recordati S.p.A.

38. Global Ischemic Heart Disease (IHD) Drugs Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Ischemic Heart Disease (IHD) Drugs Market

40. Ischemic Heart Disease (IHD) Drugs Market High Potential Countries, Segments and Strategies

40.1 Ischemic Heart Disease (IHD) Drugs Market In 2030 - Countries Offering Most New Opportunities

40.2 Ischemic Heart Disease (IHD) Drugs Market In 2030 - Segments Offering Most New Opportunities

40.3 Ischemic Heart Disease (IHD) Drugs Market In 2030 - Growth Strategies

40.3.1 Market Trend Based Strategies

40.3.2 Competitor Strategies

41. Appendix

41.1. Abbreviations

41.2. Currencies

41.3. Historic And Forecast Inflation Rates

41.4. Research Inquiries

41.5. The Business Research Company

41.6. Copyright And Disclaimer

List Of Tables

Table 1: Global Ischemic Heart Disease (IHD) Drugs Market, Overview Of Key Products - Product Examples

Table 2: Global Ischemic Heart Disease (IHD) Drugs Market Attractiveness, Factor-Wise Evaluation

Table 3: Global Ischemic Heart Disease (IHD) Drugs Market, Supply Chain Analysis

Table 4: Global Ischemic Heart Disease (IHD) Drugs Market, Major Raw Material Providers

Table 5: Global Ischemic Heart Disease (IHD) Drugs Market, Major Resource Providers

Table 6: Global Ischemic Heart Disease (IHD) Drugs Market, Major Manufacturers (Suppliers)

Table 7: Global Ischemic Heart Disease (IHD) Drugs Market, Major Distributors And Channel Partners

Table 8: Global Ischemic Heart Disease (IHD) Drugs Market, Key Technologies & Future Trends

Table 9: Global Ischemic Heart Disease (IHD) Drugs Market, Major Trends

Table 10: Global Ischemic Heart Disease (IHD) Drugs Market, Major End Users

Table 11: Global Ischemic Heart Disease (IHD) Drugs Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis

Table 12: Global Ischemic Heart Disease (IHD) Drugs Historic Market Growth, 2020-2025, $ Billion

Table 13: Global Ischemic Heart Disease (IHD) Drugs Forecast Market Growth, 2025-2030F, 2035F, $ Billion

Table 14: Global Ischemic Heart Disease (IHD) Drugs Market - TAM, US$ Billion, 2025

Table 15: Global Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 16: Global Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 17: Global Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 18: Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Anti-Dyslipidemic Drugs, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 19: Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Calcium Channel Blockers, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 20: Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Beta-Blockers, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 21: Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Angiotensin-Converting Enzyme (ACE) Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 22: Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Angiotensin II Receptor Blockers (ARBs), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 23: Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Vasodilators, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 24: Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Antithrombotic Agents, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 25: Global Ischemic Heart Disease (IHD) Drugs Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 26: Global Ischemic Heart Disease (IHD) Drugs Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 27: Asia-Pacific, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 28: Asia-Pacific, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 29: Asia-Pacific, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 30: China, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 31: China, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 32: China, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 33: India, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 34: India, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 35: India, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 36: Japan, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 37: Japan, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 38: Japan, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 39: Australia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 40: Australia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 41: Australia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 42: Indonesia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 43: Indonesia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 44: Indonesia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 45: South Korea, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 46: South Korea, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 47: South Korea, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 48: Taiwan, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 49: Taiwan, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 50: Taiwan, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 51: South East Asia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 52: South East Asia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 53: South East Asia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 54: Western Europe, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 55: Western Europe, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 56: Western Europe, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 57: UK, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 58: UK, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 59: UK, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 60: Germany, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 61: Germany, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 62: Germany, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 63: France, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 64: France, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 65: France, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 66: Italy, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 67: Italy, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 68: Italy, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 69: Spain, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 70: Spain, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 71: Spain, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 72: Eastern Europe, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 73: Eastern Europe, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 74: Eastern Europe, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 75: Russia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 76: Russia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 77: Russia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 78: North America, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 79: North America, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 80: North America, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 81: USA, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 82: USA, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 83: USA, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 84: Canada, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 85: Canada, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 86: Canada, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 87: South America, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 88: South America, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 89: South America, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 90: Brazil, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 91: Brazil, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 92: Brazil, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 93: Middle East, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 94: Middle East, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 95: Middle East, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 96: Africa, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 97: Africa, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 98: Africa, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Table 99: Global Ischemic Heart Disease (IHD) Drugs Key Competitor Estimated Market Shares, 2024, Percentage (%)

Table 100: Global Ischemic Heart Disease (IHD) Drugs Market - Company Scoring Matrix

Table 101: Pfizer Inc. Financial Performance

Table 102: F. Hoffmann-La Roche Ltd. Financial Performance

Table 103: Merck & Co. Inc. Financial Performance

Table 104: AbbVie Inc. Financial Performance

Table 105: Bayer AG Financial Performance

Table 106: Global Ischemic Heart Disease (IHD) Drugs Market, Competitive Benchmarking (In USD Billions)

Table 107: Global Ischemic Heart Disease (IHD) Drugs Market, Competitive Dashboard

Table 108: Global Ischemic Heart Disease (IHD) Drugs Market Size Gain ($ Billion), 2025 – 2030 By Country

Table 109: Global, Ischemic Heart Disease (IHD) Drugs Market Size Gain ($ Billion), Segmentation By Drug Class, 2025 – 2030

Table 110: Global, Ischemic Heart Disease (IHD) Drugs Market Size Gain ($ Billion), Segmentation By Disease Class, 2025 – 2030

Table 111: Global, Ischemic Heart Disease (IHD) Drugs Market Size Gain ($ Billion), Segmentation By End User, 2025 – 2030

List Of Figures

Figure 1: Global Ischemic Heart Disease (IHD) Drugs Market, Overview Of Key Products - Product Examples

Figure 2: Global Ischemic Heart Disease (IHD) Drugs Market Attractiveness, Factor-Wise Evaluation

Figure 3: Global Ischemic Heart Disease (IHD) Drugs Market, Supply Chain Analysis

Figure 4: Global Ischemic Heart Disease (IHD) Drugs Market, Major Raw Material Providers

Figure 5: Global Ischemic Heart Disease (IHD) Drugs Market, Major Resource Providers

Figure 6: Global Ischemic Heart Disease (IHD) Drugs Market, Major Manufacturers (Suppliers)

Figure 7: Global Ischemic Heart Disease (IHD) Drugs Market, Major Distributors And Channel Partners

Figure 8: Global Ischemic Heart Disease (IHD) Drugs Market, Key Technologies & Future Trends

Figure 9: Global Ischemic Heart Disease (IHD) Drugs Market, Major Trends

Figure 10: Global Ischemic Heart Disease (IHD) Drugs Market, Major End Users

Figure 11: Global Ischemic Heart Disease (IHD) Drugs Market, PESTEL (Political, Economic, Social, Technology, Environmental and Legal) Analysis

Figure 12: Global Ischemic Heart Disease (IHD) Drugs Historic Market Growth, 2020-2025, $ Billion

Figure 13: Global Ischemic Heart Disease (IHD) Drugs Forecast Market Growth, 2025-2030F, 2035F, $ Billion

Figure 14: Global Ischemic Heart Disease (IHD) Drugs Market - TAM, US$ Billion, 2025

Figure 15: Global Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 16: Global Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 17: Global Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 18: Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Anti-Dyslipidemic Drugs, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 19: Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Calcium Channel Blockers, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 20: Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Beta-Blockers, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 21: Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Angiotensin-Converting Enzyme (ACE) Inhibitors, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 22: Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Angiotensin II Receptor Blockers (ARBs), By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 23: Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Vasodilators, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 24: Global Ischemic Heart Disease (IHD) Drugs Market, Sub-Segmentation Of Antithrombotic Agents, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 25: Global Ischemic Heart Disease (IHD) Drugs Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 26: Global Ischemic Heart Disease (IHD) Drugs Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 27: Asia-Pacific, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 28: Asia-Pacific, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 29: Asia-Pacific, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 30: China, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 31: China, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 32: China, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 33: India, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 34: India, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 35: India, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 36: Japan, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 37: Japan, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 38: Japan, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 39: Australia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 40: Australia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 41: Australia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 42: Indonesia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 43: Indonesia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 44: Indonesia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 45: South Korea, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 46: South Korea, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 47: South Korea, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 48: Taiwan, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 49: Taiwan, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 50: Taiwan, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 51: South East Asia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 52: South East Asia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 53: South East Asia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 54: Western Europe, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 55: Western Europe, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 56: Western Europe, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 57: UK, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 58: UK, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 59: UK, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 60: Germany, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 61: Germany, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 62: Germany, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 63: France, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 64: France, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 65: France, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 66: Italy, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 67: Italy, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 68: Italy, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 69: Spain, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 70: Spain, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 71: Spain, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 72: Eastern Europe, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 73: Eastern Europe, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 74: Eastern Europe, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 75: Russia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 76: Russia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 77: Russia, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 78: North America, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 79: North America, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 80: North America, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 81: USA, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 82: USA, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 83: USA, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 84: Canada, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 85: Canada, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 86: Canada, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 87: South America, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 88: South America, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 89: South America, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 90: Brazil, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 91: Brazil, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 92: Brazil, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 93: Middle East, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 94: Middle East, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 95: Middle East, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 96: Africa, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 97: Africa, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By Disease Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 98: Africa, Ischemic Heart Disease (IHD) Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

Figure 99: Global Ischemic Heart Disease (IHD) Drugs Key Competitor Estimated Market Shares, 2024, Percentage (%)

Figure 100: Global Ischemic Heart Disease (IHD) Drugs Market - Company Scoring Matrix

Figure 101: Pfizer Inc. Financial Performance

Figure 102: F. Hoffmann-La Roche Ltd. Financial Performance

Figure 103: Merck & Co. Inc. Financial Performance

Figure 104: AbbVie Inc. Financial Performance

Figure 105: Bayer AG Financial Performance

Figure 106: Global Ischemic Heart Disease (IHD) Drugs Market, Competitive Benchmarking (In USD Billions)

Figure 107: Global Ischemic Heart Disease (IHD) Drugs Market, Competitive Dashboard

Figure 108: Global Ischemic Heart Disease (IHD) Drugs Market Size Gain ($ Billion), 2025 – 2030 By Country

Figure 109: Global, Ischemic Heart Disease (IHD) Drugs Market Size Gain ($ Billion), Segmentation By Drug Class, 2025 – 2030

Figure 110: Global, Ischemic Heart Disease (IHD) Drugs Market Size Gain ($ Billion), Segmentation By Disease Class, 2025 – 2030

Figure 111: Global, Ischemic Heart Disease (IHD) Drugs Market Size Gain ($ Billion), Segmentation By End User, 2025 – 2030

Global Complete Nutrition Products Market Landscape: Trends and Market Share to 2029

Competitive and Market Trend Analysis of Conjugate Vaccine Industry Through 2029

Industry Trends Show Cosmeceuticals Market Set to Expand at 8.8% CAGR Until 2029

Strategic Report on Cosmetic Ingredients Market: Growth Opportunities and Emerging Challenges

Uncover TBRC’s strategic outlook on technological trends, regulatory factors, and market growth in transdermal drug delivery systems.

Explore forecast data, therapeutic advancements, and pipeline progress in TBRC’s Tuberous Sclerosis Drug Market report.

Gain insights into strategic developments and market forecasts for the tissue plasminogen activator market.

Explore the impact of innovative phytocine lines on the herbal medicine market in 2025.

Cardiovascular Drugs Global Market Report 2022 – By Type (Anti-Hypertensive Drugs, Hypolipidemics, Anti Thrombotics, Other Drugs For Cardiovascular Diseases (Congestive Heart Failure, Anti-Arrhythmic And Anti-Anginal Dru...

Metabolic Disorders Drugs Global Market Report 2022 – By Type (Anti Diabetics drugs, Anti-Thyroid Drugs, Others (Hyperparathyroidism, Hypopituitarism, Hypoadrenalism)), By Distribution Channel (Hospital Pharmacies, Retai...

Edge AI Software Market Report 2026 - Global Outlook – By Component (Solution, Software Tools, Platform, Services, Training And Consulting Services, System Integration Testing, Support And Maintenance), By Data Type (Vid...

Storage Area Network (SAN) Solutions Market Report 2026 - Global Outlook – By Component (Software, Hardware, Services), By Server (Hyperscale Server SAN, Enterprise Server SAN), By Technology (Fiber Channel (FC), Fiber C...

Cardiovascular Monitoring And Diagnostic Devices And Equipment Market Report 2026 - Global Outlook – By Product Type (Cardiopulmonary Stress Testing Systems, ECG Data Management Systems, ECG Monitoring Equipment, ECG Str...

Sinus Dilation Devices Market Report 2026 - Global Outlook – By Product (Balloon Sinus Dilation Devices, Sinus Stents Or Implants), By Procedure (Standalone, Hybrid), By Application (Adult, Pediatric), By End User (Hospi...

Frequently Asked Questions

How big is the Ischemic Heart Disease (IHD) Drugs Market?

The Ischemic Heart Disease (IHD) Drugs market was valued at $6.65 billion in 2025, increased to $6.9 billion in 2026, and is projected to reach $7.99 billion by 2030.

What is the Ischemic Heart Disease (IHD) Drugs market growth?

The global Ischemic Heart Disease (IHD) Drugs market is expected to grow at a CAGR of 3.7% from 2026 to 2035 to reach $7.99 billion by 2035.

Who are the key players in Ischemic Heart Disease (IHD) Drugs market?

Some Key Players in the Ischemic Heart Disease (IHD) Drugs market Include, Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GSK PLC, Eli Lilly and

Major trend in this market includes: Regulatory Momentum And Indication Expansions Strengthening Therapeutic Advancements In Ischemic Heart Disease. For further insights on this market. request a sample here

North America was the largest region in the ischemic heart disease (IHD) drugs market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ischemic heart disease (ihd) drugs ma

Book your 30 minutes free consultation with our research experts

Contact Us